Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On June 4, 2020 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

### Therapeutic Class Reviews
- Intra-articular hyaluronic acids
- CGRP antagonists
- ICS/LAMA/LABA agents
- Non-opioid (neuropathic) pain management agents
- Nasal steroids
- Potassium binding agents
- Gout Agents
- Narcolepsy Agents
- Contraceptives, foams, and devices
- ADHD medications
- Anti-obesity medications
- Opioid dependence agents

### Drug Monographs
- Reyvow
- Oxbryta
- Adakveo
- Palforzia
- Sucraid
- Ridaura

### Prior Authorization Criteria Updates

New criteria was created for the following agents:
- Rectiv (nitroglycerin)
- Acute migraine medications (Nurtec ODT, Reyvow, Ubrelvy)

Updates were made to the criteria for the following agents:
- Entresto (sacubitril/valsartan)
- Adalimumab (Humira)
- Infliximab (Remicade)
- Maraviroc (Selzentry)
- Tofacitinib (Xeljanz)
- Ustekinumab (Stelara)
- Valbenazine (Ingrezza)
Criteria reviewed and unchanged:
- Gout agents
- Narcolepsy agents

The following drugs were added to the CCHP formulary:
- Ozempic (semaglutide), Rybelsus (semaglutide)
- Farxiga (dapagliflozin)
- Lidocaine 5% ointment
- Lidocaine/prilocaine 2.5%-2.5% cream

Guest Speaker(s)
- None

CCHP P&T Committee approved the following modifications to the formulary:

<table>
<thead>
<tr>
<th>Medication Name &amp; Dosage Strength</th>
<th>Approved Formulary Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ozempic (semaglutide)</td>
<td>Added to formulary, Tier 2 QL</td>
</tr>
<tr>
<td>Rybelsus (semaglutide)</td>
<td>Added to formulary, Tier 2 QL</td>
</tr>
<tr>
<td>Farxiga (dapagliflozin)</td>
<td>Added to formulary, Tier 2 QL</td>
</tr>
<tr>
<td>Lidocaine 5% ointment</td>
<td>Added to formulary, Tier 1</td>
</tr>
<tr>
<td>Lidocaine/prilocaine 2.5-2.5% cream</td>
<td>Added to formulary, Tier 2 QL</td>
</tr>
</tbody>
</table>

New Product Reviews (including new indications)

- Ruxience (rituximab-pvvr)
- Tazverik (Tazemetostat)
- Reyvow (Lasmiditan)
- Palforzia (Peanut allergen powder)
- Fetroja (Cefiderocol)
- Procysbi (Cysteamine bitartrate)
- Trazimera (Trastuzumab-qyyp)
- Lipiodol (Ethiodized oil)
- Vyepi (Eptinezumab-jjmr)
- Nurtec ODT (Rimegepant ODT)
- Nexletol (Bempedoic acid)
- Zerviate (Cetirizine ophthalmic)
- Sarclisa (Isatuximab-irfc)
- Trijardy XR (Empagliflozin/linagliptin/metformin ER)
- Scennesse (Afamelanotide SQ)
- Arazlo (Tazarotene) topical lotion
- Xcopri (Cenobamate) tablet
- Ajovy (Fremanezumab-vfrm)
- Isturisa (Osilodrostat) tablets
- Ontruzant (Trastuzumab-dttb)
- Koselugo (Selumetinib) capsules
- Tukysa (Tucatinib) tablets
- Pemazyre (Pemigratinib) tablets